Law360 and other legal and pharmaceutical publications wrote about our "first-of-its-kind" lawsuit alleging AbbVie and several biosimilar makers engaged in anticompetitive conduct to block competition for AbbVie's Humira, which is the world' top-selling drug.  The suit was filed on behalf of UFCW Local 1500 Welfare Fund.  Labaton Sucharow's Antitrust and Competition Litigation Co-Chair Gregory Asciolla told Law360 that the suit is "the first class action filed regarding these claims." 

Additional Coverage

AbbVie Hit with Class-Action Lawsuit Over its 'Patent Estate' to Protect Humira
Becker’s Hospital Review, March 19, 2019

AbbVie Sued for Alleged Antitrust Violations Over Blockbuster Med Humira
Law.com, March 19, 2019

Class Action Lawsuit Filed Against AbbVie and Biosimilar Developers Alleges Collusion
The Center for Biosimilars, March 19, 2019

AbbVie Faces Class Action Lawsuit from New York Grocery Union Over Humira 'Patent Thicket'
FiercePharma, March 20, 2019

AbbVie Is Sued for Using Humira Patent Deal to Block Competition in the U.S. 
STAT, March 20, 2019